¦V¤W IVF Endocrine Disorder Pubertal Development IUI

~ Endocrine Disorders ~

ˇ@

« Outline

  1. Hyperandrogenism:
  2. 1). Polycystic ovarian syndrome

    2). Cushingˇ¦s syndrome

    3). Congenital adrenal hyperplasia

    4). Androgen-secreting ovarian and adrenal tumors

    5). Androgen-producing ovarian neoplasm

    6). Stromal hyperplasia and stromal hyperthecosis

    7). Virilization during pregnancy

    8). Virilizing adrenal neoplasms

  3. Hyperprolactinemia:
  4. Thyroid Disorders:

1). Hashimotoˇ¦s thyroiditis

2). Gravesˇ¦ disease

3). Postpartum thyroid dysfunction

ˇ@

ˇ@

  1. Hyperandrogenism

ˇ@

Ÿ Hirsutism

? Definition: the presence of hair in androgen-dependent sites in which hair does not

normally appear in women. Ie. ˇ§midline hairˇ¨, eg. side burns, moustache, beard,

chest or intermammary hair, and inner thigh and midline lower back hair entering

the intergluteal area.

Distinguished from:

ƒ the most frequent manifestation of androgen excess in women.

Acne, chronic anovulation, virilization à hirsutism

Evaluation:

drug history, etc.

moon face, plethora, purple striae, dorsocervical and uspraclanicular fat pads, hair

growth pattern, etc.

a). serum androgen: total testosterone, DHEAS, and 17-hydroxyprogesteron (p 836-7)

b). If oligomenorrhea (+), check LH, FSH, prolactin, and TSH.

c). If Cushingˇ¦s syndrome is suspected, check 24-hour urine cortisol (most sensive), or

overnight dexamethasone suppression test. (p836)

ˇ@

1). Polycystic ovarian syndrome

? Clinical Definition: oligomenorrhea/amenorrhea, infertility, hirsutism, and obesity.

Diagnostic Criteria:

- hyperandrogenism, chronic anovulation, exclusion of secondary causes such as

neoplasm, hyperprolactinemia, and adult-onset congenital adrenal hyperplasia.

- An elevated LH/FSH ratio is often but not always present, and cystic ovarian

changes are usually present but not essential for diagnosis.

ƒ Sonographic Findings:

generally more than 5 microcysts in each ovary

Long-term Risks:

hair-AN syndrome (severe insulin resistance)

ˇK Treatment: (depending on patientˇ¦s goals)

ˇP oral contraceptives:

ˇP medroxyprogesterone: 20-40 mg daily in divided dosage, or 150 im. every 6ws to 3ms

ˇP GnRH analogs: leuprolide acetate im. every 28ds

ˇP glucocorticoids:

dexamethasome 0.25 mg nightly or every other nightly, monitoring of serum cortisol.

ˇP spironolactone: 25-100 mg bid

ˇP cyproterone acetate:

cyproterone acetate 100 mg qd on D5-15, and

ethinyl estradiol 30-50 m g qd on D5-26

When a desired clinical response is achieved, the dose of may be tapered gradually at 3-6

month intervals

ˇP flutamide:

ˇP temporary: shaving, etc.

ˇP permanent (electrolysis)

ˇ@

2). Cushingˇ¦s syndrome

? Causes:

Category

Cause

Relative Incidence

ACTH-dependent

Cushingˇ¦s disease

Ectopic ACTH-secreting tumors

Ectopic CRH-secreting tumors

75%

60%

rare

ACTH-independent

Adrenal cancer

Adrenal adenoma

Micronodular adrenal hyperplasia

Iatrogenic

15%

10%

rare

very common

ACTH: adenocorticotropic hormone; CRH: cortical-releasing hormone

Clinical Manifestations:

    1. increased glucocorticoid action:
    2. nitrogen wasting and a catabolic state (muscle weakness, osteoporosis, atrophy of the skin with striae, possible nonhealing ulcerations and ecchymoses, reduced immune resistance, and glucose intolerance)

    3. mineralocorticoid excess:
    4. arterial hypertention, hypokalemic alkalosis, fluid retention, pedal edema.

    5. overproduction of sex steroid precursors:

women: some degree of masculinization (hirsutisum, acne, oligomenorrhea

or amenorrhea, thinning of scalp hair)

men: some degree of feminization (gynecomastia and impotence)

ƒ Diagnostic Work-up: (Figure 25.2, p846)

Treatment:

  1. surgical removal of neoplasm
  2. several months of glucocorticoid replacement
  3. treatment of ectopic ACTH/CRH-producing neoplams:
  1. surgical treatment
  2. radiation therapy
  3. medical therapy: mitotane for inducing medical adrenalectomy

ˇ@

3). Congenital adrenal hyperplasia (CAH)

? Genetics:

Pathogenesis:

1. A relative decrease in cortisol production

2. A compensatory increase in ACTH level

3. Hyperplasia of the zona reticularis of the adrenal cortex

4. An accumulation of the precursors of the affected enzyme in the bloodstream

    1. walt-wasting CAH: the most sever form
    2. simple virilizing CAH:
    3. adult-onset CAH:

ƒ Clinical Presentation of Adult-onset CAH:

    1. PCOS (39%)
    2. Hirsutism alone without amenorrhea (39%)
    3. Cryptic (22%): hyperandrogenism but no hyperandrogenic symptoms

Lab. Testing:

1st. basal follicular 17-hydroxyprogesterone:

2nd. ACTH stimulation testing:

0.25 mg ACTH iv

1 hour later

17-hydroxyprogesterone > 1000 ng/dl

ˇK Treatment: dexamethasone

ˇ@

ˇ@

6). Stromal hyperplasia and stromal hyperthecosis

ˇ@

  1. Hyperprolactinemia

? Workup for Hyperprolactinemia: (Figure 25.4, p858)

Causes of Hyperprolactinema: (Table 25.5, p856)

ˇ@

  1. Thyroid Disorders

ˇ@

¤ Evaluations:

total serum T4, TSH, T3 (in pregnancy, oral contraceptive, estron replacement hepatitis,

and genetic abnormalities of TBG)

Antithyroglobulin antibodies, antimicrosomal antibodies, antibodies to T3 and T4, thyoid-stimulating antibodies (TSAb) or thyroid stimulating immunoglobulin (TSI), TSH-binding inhibitor immunoglobulin (TBII), thyroid growth-promoting immunoglobulin (TGI)

ˇ@

1).Hypothyroidism

ˇ@

? Causes: (Table25.9, p868)

Congenital absence of thyroid gland, external thyroid gland radiation, familial disorders and thyroxine synthesis, Hasnimotoˇ¦s thyroiditis, 131Iablation for Gravesˇ¦ disease, ingestion of antithyroid drugs, iodine deficiency, idiopathic myxedema, surgical removal of thyroid gland

Hypothalamic TRH deficiency, pituitary or hypothalamic tumors or diseases.

Reproductive Effects of Hypothyroidism:

decreased fertility from ovulatory difficulties, menstrual disturbance, luteal phase defect, and

hyperprolactinemia

ƒ Hashimotoˇ¦s Thyroiditis:

  1. Clinical Characteristics and Diagnosis:

cold intolerance, constipation, carotene deposition in the periorbital region, carpal tunnel

syndrome, dry skin, fatigue, hair loss, lethargy, and weight gain.

- Lab. Data: elevated TSH, elevated antithyroglobulin and antimicrosomal antibody

B. Treatment: thyroxine replacement

- monitor by TSH

ˇ@

2).Hyperthyroidism

? Causes:

Reproductive Effects of Hyperthyroidism:

weight loss, menstrual irregularity, increased risk of spontaneous abortion, increased incidence of

congenital anomalies, fetal neonatal hyperthyroidism.

ƒ Gravesˇ¦ Disease:

  1. Clinical Characteristics and Diagnosis:

B. Treatment:

w most commonly utilized definitive treatment in nonpregnant women

w single dose

w Any woman of childbearing age should be tested for pregnancy before use of 131I

w Propylthiouracil (PTU): the drug of choice in pregnancy

PTU 100 mg q8h over 1 month

Monitored weekly by evaluation of appetite, emotional lability, insomnia, and tremor

General rule: to lower the dosage by 50% when thyroid function returns to normal.

w Methimazole: most prescribed for nonpregnant women.

Methimazole 10 mg q8-24h

General rule: as PTU

Currently less commonly used as definite therapy

ˇ@

Filename: Endocrine Disorders

ˇ@